Please assess the completion status of the following clinical trial:

Trial Title: Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of cystic fibrosis (CF) and homozygous for F508del-CFTR mutation~* Forced expiratory volume in 1 second (FEV1) of at least 40% of predicted normal for age, gender, and height~* Willing to use at least 2 highly effective birth control methods during the study~* No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator~* Able to understand and comply with protocol requirements, restrictions, and instructions and likely to complete the study as planned, as judged by the investigator~Exclusion Criteria:~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject~* Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study~* History of alcohol, medication or illicit drug abuse within one year prior to Day 1~* Abnormal liver function \>=3 x the upper limit of normal~* Abnormal renal function at Screening~* History of solid organ or hematological transplantation~* Pregnant or breast-feeding (for women)~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to screening~* Previous participation in a VX-809 study~* Used inhaled hypertonic saline treatment~* Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP3A4)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
- Ivacaftor (Type: EXPERIMENTAL): Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).

Based on this trial design, predict the completion outcome and termination type (if applicable).